长春高新：子公司替勃龙片和绒促卵泡激素α N02注射液在境内获批上市

Group 1 - The core point of the article is that Changchun High-tech (000661) announced the approval of two drugs by the National Medical Products Administration for market launch in China [1] Group 2 - Changchun High-tech's subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the drug registration certificate for Tebentafusp tablets, which has been approved for sale in the domestic market [1] - The company also announced that its subsidiary received the drug registration certificate for Follitropin αN02 injection, which has also been approved for sale in the domestic market [1]